Erschienen in:
01.08.2011 | Viewpoint
Estrogen receptor degradation: a CUE for endocrine resistance?
verfasst von:
Elizabeth A Musgrove
Erschienen in:
Breast Cancer Research
|
Ausgabe 4/2011
Einloggen, um Zugang zu erhalten
Abstract
Despite the undoubted success of adjuvant endocrine therapies that target the estrogen receptor pathway, not all women with estrogen receptor-positive breast cancer respond to these therapies, and many who initially respond will subsequently relapse. Deregulation of various aspects of estrogen receptor signaling has been highlighted as a mechanism of resistance and as a basis for alternative therapeutic approaches. However, a recent publication refocuses attention on the estrogen receptor itself by showing that the ubiquitin-binding CUE domain-containing protein 2 is a regulator of estrogen receptor protein degradation and a marker of endocrine resistance in breast cancer.